Myriad Genetics MYGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cancer Care Continuum | $120.2M+4.0% | —— | —— | —— | $115.6M— | |
| Mental Health | $38.3M+23.5% | —— | —— | —— | $31M-27.1% | |
| Prenatal Health | $41.9M-15.0% | —— | —— | —— | $49.3M— | |
| Revenue by Geography | ||||||
| RoW | $13.4M-6.3% | $13.3M-11.9% | $14M-19.1% | $14.9M-10.8% | $14.3M-24.7% | |
| U.S. | $187M+3.0% | $196.5M+0.5% | $191.7M-2.2% | $198.2M+1.7% | $181.6M-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Myriad Genetics break its business down?
- Myriad Genetics (MYGN) reports revenue by product across 5 parts — Cancer Care Continuum, Hereditary Cancer, Mental Health, Prenatal Health and Prenatal. Each is extracted from the segment footnotes and tracked over time.
- Where does Myriad Genetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Myriad Genetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
